SOT109
Colorectal Cancer, GI Cancers
PreclinicalActive
Key Facts
About SOTIO Biotech
SOTIO Biotech is a private, clinical-stage biotech company headquartered in Prague, Czech Republic, with a strategic presence in the US and Europe. It is developing a diversified pipeline of immunotherapies, including the IL-15 superagonist nanrilkefusp alfa (SOT201) and several ADC candidates (SOT106, SOT109) targeting solid tumors. Backed by the PPF Group, the company leverages proprietary and partnered technology platforms to translate compelling science into patient benefit, with a business model centered on therapeutic development.
View full company profile